Mikafungin Accord (Micafungin)

Micafungin, the active ingredient in Mikafungin Accord, is an echinocandin presented as an injectable solution for intravenous use. It treats systemic fungal infections such as invasive candidiasis, esophageal candidiasis, Candida peritonitis, and febrile neutropenia in immunocompromised patients.

GNH USA supplies Mikafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal that targets fungal cell wall synthesis.

Invasive candidiasis: clears bloodstream Candida infections in high‑risk patients. Esophageal candidiasis: resolves mucosal Candida infection of the esophagus. Candida peritonitis: treats intra‑abdominal Candida infection. Febrile neutropenia: provides empirical antifungal coverage in neutropenic individuals.

Common Side Effects: - Infusion‑related reactions such as flushing or chills. - Fever or rigors during administration. - Nausea or vomiting. - Headache. - Elevated liver enzymes. - Rash or pruritus.

Serious or Rare Side Effects: - Severe hepatic failure or jaundice. - Anaphylactic or severe hypersensitivity reactions. - Acute renal dysfunction. - Neutropenia or other hematologic abnormalities. - Cardiac arrhythmias. - Unexplained sudden death.

Precautions should be taken when using Micafungin injectable solution.

Renal impairment: monitor kidney function during therapy. Hepatic impairment: assess liver enzymes before and during treatment. Concomitant azole antifungals: avoid potential pharmacokinetic interactions. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Infusion rate: administer over the recommended period to reduce infusion‑related reactions. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase micafungin exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce micafungin exposure. - Co‑administration with other echinocandins: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): monitor for additive antifungal effect. - Immunosuppressants (e.g., tacrolimus): observe drug levels. - Warfarin: monitor INR for potential anticoagulant effect changes.